Long-term Results of Reduced-fluence Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy
- Authors
- Han, Ji Yun; Kim, Seong-Woo; Oh, Jaeryung
- Issue Date
- 6월-2017
- Publisher
- KOREAN OPHTHALMOLOGICAL SOC
- Keywords
- Polypoidal choroidal vasculopathy; Reduced fluence photodynamic therapy; Vascular endothelial growth factor
- Citation
- JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, v.58, no.6, pp.646 - 652
- Indexed
- KCI
- Journal Title
- JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY
- Volume
- 58
- Number
- 6
- Start Page
- 646
- End Page
- 652
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/83289
- DOI
- 10.3341/jkos.2017.58.6.646
- ISSN
- 0378-6471
- Abstract
- Purpose: To evaluate the long-term effects of reduced-fluence photodynamic therapy (RF-PDT) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for polypoidal choroidal vasculopathy (PCV). Methods: Twenty-two eyes of 21 patients with PCV that were followed up for more than 24 months after RF-PDT and anti-VEGF combination therapy were retrospectively reviewed. The patients received intravitreal anti-VEGF (bevacizumab 1.25 mg, ranibizumab 0.5 mg, or aflibercept 2.0 mg) within 7 days of PDT. Patients were retreated with either RF-PDT and anti-VEGF injection, or with only anti-VEGF injection, as indicated. The main outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT), which were measured before and after combination therapy. Results: During follow-up, the mean logMAR BCVA significantly improved from 0.75 at baseline to 0.54 at 12 months and 0.52 at 24 months (p = 0.009 and p = 0.032, respectively). The mean CFT significantly decreased from 409.8 mu m at baseline to 234.1 mu m at 12 months and 245.9 mu m at 24 months (p < 0.001 and p = 0.001, respectively). In 20 eyes (90.9%), the BCVA remained stable or improved. Conclusions: The efficacy of this combination therapy for 24 months resulted in stabilized vision and anatomical improvement. RF-PDT combined with intravitreal anti-VEGF injection could be an effective treatment modality for patients with PCV.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.